Shelf life (days): 1460.0
Formulation: A solid
Formal Name: trans-N-methyl-4-(methyl-13C-d3-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide
Purity: ≥99% deuterated forms (d1-d3)
Formula Markup: C14[13C]H20D3N5O2S
Formula Weight: 341.5
CAS Number: 2750534-84-8
Notes: Oclacitinib-13C-d3 is intended for use as an internal standard for the quantification of oclacitinib (Item No. 18722) by GC- or LC-MS. Oclacitinib is an inhibitor of the JAK family kinases JAK1, JAK2, JAK3, and TYK2 (IC50s = 10, 18, 99, and 84 nM, respectively).{30396} It is selective for JAK kinases over a panel of 38 additional kinases at 1 μM. Oclacitinib inhibits LPS-induced increases in IL-12 and TNF-α levels in murine bone marrow-derived dendritic cells (BMDCs) in a concentration-dependent manner.{48761} Topical administration of oclacitinib (0.1, 0.25, and 0.5%) reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of allergic dermatitis induced by toluene-2,3-diisocyanate (TDI). Formulations containing oclacitinib have been used in the treatment of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs.
English
Deutsch
